Insiders With Their Considerable Ownership Were the Key Benefactors as Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584) Touches CN¥3.3b Market Cap
Insiders With Their Considerable Ownership Were the Key Benefactors as Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584) Touches CN¥3.3b Market Cap
Key Insights
主要見解
- Nanjing Hicin Pharmaceutical's significant insider ownership suggests inherent interests in company's expansion
- The top 2 shareholders own 52% of the company
- Using data from company's past performance alongside ownership research, one can better assess the future performance of a company
- 南京希欽藥業的重大內部人持股表明了公司擴張的內在利益
- 最大的兩個股東擁有公司52%的股份
- 使用來自公司過去業績的數據以及所有權研究,可以更好地評估公司未來的業績
To get a sense of who is truly in control of Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584), it is important to understand the ownership structure of the business. We can see that individual insiders own the lion's share in the company with 62% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
要弄清楚誰真正控制了南京希欽藥業股份有限公司(深交所:300584),瞭解該企業的所有權結構是很重要的。我們可以看到,個人內部人士擁有公司的最大份額,擁有62%的股份。換句話說,該集團將從他們對公司的投資中獲得最大(或損失最大)。
Clearly, insiders benefitted the most after the company's market cap rose by CN¥550m last week.
顯然,在該公司市值上週上漲5.5億元后,內部人士受益最大。
Let's delve deeper into each type of owner of Nanjing Hicin Pharmaceutical, beginning with the chart below.
讓我們從下面的圖表開始,更深入地調查南京希信藥業的每一種類型的所有者。
See our latest analysis for Nanjing Hicin Pharmaceutical
查看我們對南京希欽藥業的最新分析
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231013/0-bbe63fdf7836b4cc994451bedd73cbc5-0-9baadb42c1dbff85b5d2bf13c1235eb8.png/big)
What Does The Institutional Ownership Tell Us About Nanjing Hicin Pharmaceutical?
關於南京希欽藥業,機構持股告訴了我們什麼?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
許多機構以一個接近當地市場的指數來衡量它們的表現。因此,他們通常更關注那些被納入主要指數的公司。
Less than 5% of Nanjing Hicin Pharmaceutical is held by institutional investors. This suggests that some funds have the company in their sights, but many have not yet bought shares in it. So if the company itself can improve over time, we may well see more institutional buyers in the future. We sometimes see a rising share price when a few big institutions want to buy a certain stock at the same time. The history of earnings and revenue, which you can see below, could be helpful in considering if more institutional investors will want the stock. Of course, there are plenty of other factors to consider, too.
機構投資者持有南京希信藥業不到5%的股份。這表明,一些基金瞄準了該公司,但許多基金尚未購買該公司的股票。因此,如果公司本身能夠隨著時間的推移而改善,我們很可能會在未來看到更多的機構買家。當幾家大機構想要同時購買某隻股票時,我們有時會看到股價上漲。下面你可以看到的收益和收入的歷史,可能有助於考慮是否有更多的機構投資者會想要這只股票。當然,還有很多其他因素需要考慮。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231013/0-bbe63fdf7836b4cc994451bedd73cbc5-1-0c8762920189c7d1f0b39d93e10a114b.png/big)
We note that hedge funds don't have a meaningful investment in Nanjing Hicin Pharmaceutical. Looking at our data, we can see that the largest shareholder is Yu Ping Cao with 42% of shares outstanding. With 10.0% and 6.7% of the shares outstanding respectively, Xiao Qun Jiang and Xiao Quan Liu are the second and third largest shareholders.
我們注意到,對沖基金沒有對南京希信藥業進行有意義的投資。看看我們的數據,我們可以看到,第一大股東是喻屏曹操,持有42%的流通股。蔣小群和劉小泉分別持有10.0%和6.7%的流通股,是第二大股東和第三大股東。
After doing some more digging, we found that the top 2 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.
在進一步挖掘後,我們發現,前兩名股東共同控制著公司一半以上的股份,這意味著他們擁有相當大的權力來影響公司的決策。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held.
雖然研究一家公司的機構持股可以增加你的研究價值,但研究分析師的建議以更深入地瞭解一隻股票的預期表現也是一個很好的做法。目前,我們沒有注意到分析師對該股的報道,因此該公司不太可能被廣泛持有。
Insider Ownership Of Nanjing Hicin Pharmaceutical
南京希欽藥業的內部人所有權
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
公司內部人的定義可能是主觀的,而且在不同的司法管轄區之間確實有所不同.我們的數據反映了個別內部人士,至少捕捉到了董事會成員.公司管理層對董事會負責,董事會應代表股東的利益.值得注意的是,有時最高層管理人員本身也是董事會成員.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
大多數人認為內部人持股是積極的,因為它可以表明董事會與其他股東很好地結盟.然而,在某些情況下,太多的權力集中在這個群體中.
It seems that insiders own more than half the Nanjing Hicin Pharmaceutical Co., Ltd. stock. This gives them a lot of power. Given it has a market cap of CN¥3.3b, that means they have CN¥2.1b worth of shares. Most would be pleased to see the board is investing alongside them. You may wish todiscover (for free) if they have been buying or selling.
看來,內部人士持有南京希欽藥業股份有限公司一半以上的股份。這給了他們很大的權力。鑑於它的市值為人民幣33億元,這意味著他們擁有價值人民幣21億元的股票。大多數人會高興地看到董事會與他們一起投資。您可能希望發現(免費)如果他們一直在買入或賣出。
General Public Ownership
一般公有制
The general public, who are usually individual investors, hold a 34% stake in Nanjing Hicin Pharmaceutical. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
公眾通常是個人投資者,他們持有南京希欽藥業34%的股份。這種規模的所有權雖然可觀,但如果決策與其他大股東不同步,可能不足以改變公司政策。
Next Steps:
接下來的步驟:
It's always worth thinking about the different groups who own shares in a company. But to understand Nanjing Hicin Pharmaceutical better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Nanjing Hicin Pharmaceutical (at least 1 which is a bit concerning) , and understanding them should be part of your investment process.
擁有一家公司股票的不同集團總是值得考慮的。但要更好地瞭解南京希欽藥業,還需要考慮許多其他因素。例如,考慮一下無處不在的投資風險幽靈。我們已經確定了三個警告信號與南京希信藥業合作(至少1家,這有點令人擔憂),瞭解他們應該是你投資過程的一部分。
Of course this may not be the best stock to buy. So take a peek at this free free list of interesting companies.
當然了這可能不是最值得購買的股票。。所以讓我們來看看這個免費 免費有趣的公司名單。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的數位是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間.這可能與全年的年度報告數位不一致.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫.或者,也可以給編輯組發電子郵件,地址是暗示Wallst.com。
本文由Simply Wall St.撰寫,具有概括性.我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議.它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況.我們的目標是為您帶來由基本面數據驅動的長期重點分析.請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內.Simply Wall St.對上述任何一隻股票都沒有持倉.